Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04150887 · ClinicalTrials.gov registry record · Phase 1

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

A Phase 1 study of Leukemia, Myeloid, Acute, sponsored by OncoVerity.

Active
Registry status
Phase 1
Development phase
61
Enrollment target
20
Study locations

NCT04150887 is a Phase 1 study of Leukemia, Myeloid, Acute that is active but no longer recruiting, run by OncoVerity. The registered enrollment target is 61 participants, below the 114-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04150887, a Phase 1 study of Leukemia, Myeloid, Acute, is active but no longer recruiting, sponsored by OncoVerity.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
61 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).

Conditions Studied

Leukemia, Myeloid, Acute

Interventions

  • DRUG Venetoclax
  • DRUG Azacitidine
  • DRUG Cusatuzumab

Study Locations (20)

Other

  • Universitaetsklinik Hamburg-Eppendorf - Hamburg
  • Universitaetsklinikum Leipzig - Leipzig
  • Klinikum der Universitaet Muenchen - München
  • Szpital Uniwersytecki w Krakowie - Krakow
  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi - Lodz

New York

  • Roswell Park Cancer Institute - Buffalo
  • Weill Cornell Medicine - New York
  • Memorial Sloan Kettering Cancer Center - New York
  • University of Rochester - Rochester

Alberta

  • Tom Baker Cancer Centre - Calgary
  • University of Alberta Hospital - Edmonton

California

  • City of Hope - Duarte

Kentucky

  • Norton Cancer Institute - Louisville

Michigan

  • Barbara Ann Karmanos Cancer Institute - Detroit

Pennsylvania

  • University of Pittsburgh School of Medicine - Pittsburgh

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2019-12-23
Est. Completion 2026-05-15
Phase Phase 1

Sponsor

OncoVerity

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04150887

The ClinicalTrials.gov registry entry for NCT04150887 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 114-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (46% lower). The listed sponsor is OncoVerity, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Leukemia, Myeloid, Acute appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT04150887 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, New York, Alberta.

Frequently Asked Questions

What is clinical trial NCT04150887 about?

NCT04150887 is a clinical study titled "Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia". The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).

What is the current status of trial NCT04150887?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2019-12-23. Estimated completion is 2026-05-15.

What conditions does trial NCT04150887 study?

This clinical trial studies the following conditions: Leukemia, Myeloid, Acute.

What interventions are being tested in trial NCT04150887?

The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Cusatuzumab (DRUG).

Who is sponsoring clinical trial NCT04150887?

This trial is sponsored by OncoVerity, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04150887 being conducted?

This trial has 20 study locations across California, Kentucky, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia, Myeloid, Acute

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Leukemia, Myeloid, Acute

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.